Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.74 |
| ▸ | CASP2 | P42575 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.69 |
| ▸ | NAAA | Q02083 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 2/20 | 0.62 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.59 |
| ▸ | SELP | P16109 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9964261 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL8695820 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL16658797 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| Hexadecanoic Acid Propylamide SCHEMBL1457463 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL5173746 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL18812629 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL9097339 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL12460084 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL9964260 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 | |
| SCHEMBL16658798 | 1.00 | FAAH (0.74) | FAAHCASP2DNM1NAAACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | UT-BATTELLE, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-12018125-B2 | Block-copolymers for the delivery of active agents | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2024-06-25 | — | — | US | disclosed |
| US-20230366059-A1 | METHOD FOR SEPARATION OF ADJACENT LANTHANIDE ELEMENTS | UT-BATTELLE, LLC | 2023-11-16 | — | — | US | disclosed |
| EP-4175940-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-Battelle, LLC (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022148821-A1 | USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF | LOCKI THERAPEUTICS LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022148822-A1 | USP5 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF | LOCKI THERAPEUTICS LIMITED (GB) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022010758-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20220002840-A1 | METHODS FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS USING DIGLYCOLAMIDE DERIVATIVES | BATTELLE ENERGY ALLIANCE, LLC | 2022-01-06 | — | — | US | disclosed |
| US-20220002229-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC | 2022-01-06 | — | — | US | disclosed |
| US-11040296-B2 | Lipophilic diglycolamide compounds for extraction of rare earth metals from aqueous solutions | UT-BATTELLE, LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190344198-A1 | LIPOPHILIC DIGLYCOLAMIDE COMPOUNDS FOR EXTRACTION OF RARE EARTH METALS FROM AQUEOUS SOLUTIONS | UT-BATTELLE, LLC | 2019-11-14 | — | — | US | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| US-9199948-B2 | 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-12-01 | — | — | US | disclosed |
| WO-2015107170-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | ALPHABETA AB (SE) | 2015-07-23 | — | — | WO | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-04-23 | — | — | US | disclosed |
| EP-0912465-B1 | IMPROVED LITHIUM AND AMINE DISSOLVING METAL REDUCTION | ALLERGAN SALES INC (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-0912465-A1 | IMPROVED LITHIUM AND AMINE DISSOLVING METAL REDUCTION | Allergan Sales, Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998003451-A1 | IMPROVED LITHIUM AND AMINE DISSOLVING METAL REDUCTION | ALLERGAN SALES, INC. (US) | 1998-01-29 | — | — | WO | disclosed |
| US-5675038-A | Lithium and amine dissolving metal reduction | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040296-B2 | Lipophilic diglycolamide compounds for extraction of rare earth metals from aqueous solutions | GBA1, GLA, GAA | FAAH 2615/4885CASP2 4280/4885DNM1 2085/4885 |
| US-20190344198-A1 | LIPOPHILIC DIGLYCOLAMIDE COMPOUNDS FOR EXTRACTION OF RARE EARTH METALS FROM AQUEOUS SOLUTIONS | GBA1, GLA, GAA | FAAH 2615/4885CASP2 4280/4885DNM1 2085/4885 |
| US-12398444-B2 | Diglycolamide derivatives for separation and recovery of rare earth elements from aqueous solutions | GNE, GALE, ARGLU1 | FAAH 4539/4885CASP2 4128/4885DNM1 3816/4885 |
| US-20220002229-A1 | DIGLYCOLAMIDE DERIVATIVES FOR SEPARATION AND RECOVERY OF RARE EARTH ELEMENTS FROM AQUEOUS SOLUTIONS | GNE, GALE, ARGLU1 | FAAH 4539/4885CASP2 4128/4885DNM1 3816/4885 |
| US-12018125-B2 | Block-copolymers for the delivery of active agents | NR0B1, NR0B2, OGFR | FAAH 3804/4885CASP2 4665/4885DNM1 4428/4885 |
| US-20150111935-A1 | NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS | TRPV1, TRPA1, P2RX3 | FAAH 193/4885CASP2 858/4885DNM1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.